Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Conditions: Acute Lymphoblastic Leukemia; Myeloblastic Leukemia; Biphenotypic Acute Leukemia; Malignant Lymphoma; Myelodysplastic Syndromes; Juvenile Myelomonocytic Leukemia Intervention: Combination Product: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abatacept | Allergy & Immunology | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Orencia | Pediatrics | Research | Transplants